Mechanism-Driven Research.
FOCUSED ON THE CLINICAL APPLICATION OF POLYPHENOLS
KBS Research is a physician-led research and development company.
By combining gastroenterology, microbiome science, polyphenol chemistry, and human clinical research, we develop formulations to address the biological mechanisms underlying digestive and metabolic dysfunction.
BUILT WHERE FOUR DISCIPLINES MEET
We identify promising compounds, investigate their mechanisms, validate their effects, and translate research into clinically studied products.
KBS Research operates at the intersection of:
• Gastroenterology: Clinical experience and direct patient observation.
• Microbiome Science: How microbes shape human health.
• Polyphenol Chemistry: Plant compounds with measurable biological action.
• Clinical Validation: Formulations tested in structured, published human studies.
WHAT'S ACTUALLY HAPPENING IN THE GUT
Looking Beyond Symptoms
Symptoms often cluster into diagnoses such as IBS, SIBO, chronic bloating, and GERD. While these labels help define a condition, they do not always explain its biological drivers.
Bloating. Reflux. Abdominal discomfort. Digestive irregularity.
These symptoms are usually the surface of deeper biological mechanisms. At KBS Research, we focus on understanding those mechanisms and their role in digestive health.
WHY POLYPHENOLS
Polyphenols as therapeutic agents.
Not wellness ingredients.
Polyphenols are plant-derived bioactive compounds with documented antimicrobial, anti-inflammatory, microbiome-modulating, and metabolic effects.
At KBS Research, we focus on identifying combinations that produce measurable biological outcomes and validating them through structured research.
Because polyphenols interact with microbial communities, fermentation pathways, inflammatory signalling, and barrier function, they are uniquely suited to mechanism-based intervention.
Each KBS formulation is built around one of these mechanisms. Not a list of ingredients with a marketing narrative.
Fermentation.
How microbial fermentation in the small intestine produces gas where it does not belong, and how polyphenol-based formulations help modulate the organisms responsible for that gas production.
Containment.
Why reflux is a pressure and motility problem before it is an acid problem, and how supporting the stomach's one-way flow differs from simply suppressing acid.
Motility + Movement.
The digestive system is designed to move. We explore the mechanisms that influence gastric emptying, intestinal transit, and digestive flow, and how changes in movement affect symptoms throughout the gastrointestinal tract.
Microbiome and Balance.
Why short-term symptom relief does not hold without ecosystem stability, and how polyphenols influence microbial balance.
A RESEARCH-DRIVEN DEVELOPMENT ENGINE
From compound to clinical use, with the same rigor at every gate.
Clinical Research
- Structured human studies
- Peer-reviewed publications
- Academic collaborations
Formulation Science
- Mechanism-first development
- Synergistic polyphenol combinations
- Targeted applications
Quality and Compliance
- NSF Certified for Sport
- cGMP-compliant manufacturing
- Third-party testing
This is not consumer wellness.
This is evidence-led product development.
MECHANISMS APPLIED
Clinically studied formulations built around
specific biological mechanisms.
Atrantil
Mechanism: Fermentation.
A clinically studied polyphenol formulation designed to address methane-associated fermentation in the small intestine and support reduction of bloating and abdominal discomfort.
Atrantil Pro
Mechanism: Fermentation.
Practitioner channel. Enhanced professional-strength formulation developed for healthcare practitioner distribution and clinical case management.
Re:flux
Mechanism: Motility, balance, inflammation and LES function.
A polyphenol-based formulation that supports upper GI comfort and reflux-associated symptoms. When the stomach empties too slowly, pressure builds, and the LES is pushed open. Re:flux supports motility, gastric emptying, and healthy pressure to keep the system moving one way, not just suppress acid.
VALIDATED THROUGH INDEPENDENT STUDY
Outcomes measured
in real patients.
Across two formulations and more than a decade of structured study.
Atrantil: Studied in a randomized, double-blind, placebo-controlled trial and a real-world case series of IBS-C patients:
- 88% of patients responded across abdominal pain, bloating, and constipation.
- Significant improvement versus placebo in bloating and constipation (p<0.001).
Re:flux: Studied in patients with endoscopically confirmed chronic GERD, compared with usual care:
- 91.5% had clinically meaningful improvement in reflux symptoms.
- 81% reported complete symptom resolution, versus 16% on usual care.
A label is not an explanation.
Mechanism is.
Start with understanding.
